Dopar Articles
Sanofi-Synthelabo to buy out Indian JV
30 May 2001
Neurologists favor dopamine agonists for Parkinson's
24 January 2001
Indian price moves for 45 formulations
23 January 2001
Overseas sales boost Orion Pharma
10 November 2000
Draxis gets Canadian approval for Permax
3 November 2000
Pharmacia/BI's Mirapex shows less risk of motor complications
19 October 2000
Novartis/Orion seek entacapone use in early Parkinson's disease
18 October 2000
Orion to develop combo Parkinson's drug
7 September 2000
Pharmacia's DAs as first-line therapy in PD
20 June 2000
Indian NPPA imposes drug price changes
23 May 2000
AstraZeneca's remacemide, combo potential for PD?
27 April 2000
Teva and Lundbeck boosted on PD drug
12 April 2000
Lundbeck and Teva hook up in CNS
25 November 1999
Novartis gains FDA backing for Comtan
21 October 1999
SB to purchase $10m stake in SkyePharma
5 August 1999
Phase II results with SIBIA's altinicline
29 July 1999
R-PR Begins Rilutek Trial In Parkinson's
25 November 1998
SB's Requip Effective Parkinson's Adjunct
29 October 1998
SmithKline Beecham's Requip Effective Parkinson's Adjunct
23 October 1998
Novartis' Comtan Gets European Union Approval
23 September 1998
Forecasts For Global CNS Growth
23 June 1998
Euro CPMP April Plenary Meeting
18 June 1998
Cell Genesys Sees Success With PD Gene Therapy
4 June 1998
SkyePharma Benefits From Lilly Trial Advance
15 May 1998
Levodopa Concerns "May Not Be Justified"
7 May 1998
Pramipexole Approved In The European Union
5 March 1998
Asta Comes Through Tough Year, Looks To Expansion
4 March 1998
Discovery's Parkinson's Patch Effective In Phase II Trial
17 February 1998
NeuroSearch Sees Successful Product Year
27 November 1997
SB's ReQuip Launched In USA
30 October 1997
Pramipexole Approved By The EMEA
23 October 1997
First COMT Inhibitor For Parkinson's Reaches Market
1 October 1997
SB's Requip Gets Approval In The USA
25 September 1997
Mirapex Cuts Levodopa Reliance
25 September 1997
First Jago Approval
19 May 1997
Long-Term Data With SB's Ropinirole
22 April 1997
Entacapone And Tolcapone Near Market Introduction
26 March 1997
P&U Launches Cabaser In The UK
26 March 1997
P&U Launches Dostinex In The USA
20 March 1997
Discovery Therapeutics' Parkinson's Patch
17 February 1997
Roche Enters New Product Phase With Bright Prospects
17 February 1997
Parkinson's Patch Enters Phase II
25 November 1996
Amgen Initiates GDNF Trial In Parkinson's
19 August 1996
First Launch In Japan For Talipexole
22 July 1996
Sandoz To License Orion Parkinson's Drug
4 March 1996
EMEA Reports Successes In Inaugural 1995
5 February 1996
CPMP January Plenary Meeting
29 January 1996
P&U Files In USA For Parkinson's Drug
15 January 1996
Novel Drugs Will Drive Euro Anti-Parkinson's Market
27 November 1995
Disappointing Second Quarter From Teva
14 August 1995
Interneuron Starts Dihydrexidine Trial
29 May 1995
Cell-Based Therapies For Neurological Disease
5 December 1994
WEST POINT EXPANDS PRODUCT LINE
9 May 1994
DEPRENYL ACQUIRES PARKINSON'S DRUG
28 February 1994
WILL CHIROS FLOAT TO THE TOP?
15 November 1993
DUPONT MERCK TO PROMOTE LAMICTAL
16 August 1993
THREE-WAY GENERIC AGREEMENT
31 May 1993
US FDLI PHARMACEUTICAL UPDATE MEETING
31 May 1993
WORLD CNS MARKET IS LARGE AND FRAGMENTED
22 February 1993
FOLLOW-UP RESULTS OF DATATOP STUDY
1 February 1993
NEW APPROACHES IN TREATING PARKINSONISM
7 December 1992
TEVA AND DU PONT MERCK SALES DEAL
12 October 1992
EFFICACY/POTENCY DEBATE ON LEVODOPA
6 January 1992
ROBERTS PURCHASES RIGHTS TO DOPAR
6 January 1992
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
